High Dose Vitamin D3 in Crohn's Disease

Inclusion Criteria: * a prior diagnosis of Crohn's disease in clinical remission for at least 28 days with a Harvey-Bradshaw index less than or equal to 4 * All maintenance therapies for Crohn's disease will be required to be at stable dose for at least 3 months before randomization, with no systemic steroid therapy within 4 weeks. * Vitamin D supplements will be discontinued at least 6 weeks before randomization. Exclusion Criteria: * Women of child bearing potential who are considering pregnancy during the study period, currently pregnant, or unwilling to use contraception to avoid pregnancy * Participants with renal insufficiency (serum creatinine greater than 150 umol/L), sarcoidosis, hyperparathyroidism, malignancy, or any other disorder that may lead to hypercalcemia * Patients with short-gut syndrome or a serum albumin less than 32 g/L * Concomitant therapy with thiazide diuretics, barbiturates, digitalis, or supplemental products containing vitamin D